Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the weight loss drugs market, status of the weight loss drug pill, revised ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the ...

David Ricks “We have said it’s not for us right now,” said Ricks. Reuters noted that Ricks is much bolder than his predecessors in terms of acquisitions, after years when Lilly tried to make ...

Eli Lilly's chief executive, chairman and president John Lechleiter is to step down in December, and will be replaced David Ricks, who currently leads the company’s bio-medicines division.

Eli Lilly and Co. CEO David Ricks—IBJ’s newsmaker of the year in 2023—returns to the newsmaker list in 2024 after a year that included a stock price that skyrocketed to an all-time high of $ ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

Buried in the news from last month was an interesting nugget posted by Fierce Pharma: “Following a dinner at Trump’s Mar-a-Lago estate last week, Eli Lilly CEO David Ricks pointed to raising ...

Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...